{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,25]],"date-time":"2026-01-25T03:59:22Z","timestamp":1769313562121,"version":"3.49.0"},"reference-count":23,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2017,2,1]],"date-time":"2017-02-01T00:00:00Z","timestamp":1485907200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2017,2]]},"DOI":"10.1016\/j.ygyno.2016.11.043","type":"journal-article","created":{"date-parts":[[2016,12,5]],"date-time":"2016-12-05T07:30:27Z","timestamp":1480923027000},"page":"279-284","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"title":["Phase II study of irinotecan in combination with bevacizumab in recurrent ovarian cancer"],"prefix":"10.1016","volume":"144","author":[{"given":"Fernanda","family":"Musa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bhavana","family":"Pothuri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephanie V.","family":"Blank","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huichung T.","family":"Ling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James L.","family":"Speyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Curtin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leslie","family":"Boyd","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaochun","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Judith D.","family":"Goldberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Franco","family":"Muggia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amy","family":"Tiersten","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2016.11.043_bb0005","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3322\/caac.21166","article-title":"Cancer statistics, 2013","volume":"63","author":"Siegel","year":"2013","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.ygyno.2016.11.043_bb0010","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1073\/pnas.85.4.1060","article-title":"Involvement of DNA topoisomerase I in transcription of human ribosomal RNA genes","volume":"85","author":"Zhang","year":"1988","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ygyno.2016.11.043_bb0015","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1159\/000012076","article-title":"Phase II study of irinotecan and cisplatin as first-line chemotherapy in advanced or recurrent cervical cancer","volume":"58","author":"Sugiyama","year":"2000","journal-title":"Oncology (Williston Park)"},{"key":"10.1016\/j.ygyno.2016.11.043_bb0020","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1093\/jjco\/29.9.434","article-title":"A pilot study of CPT-11 and cisplatin for ovarian clear cell adenocarcinoma","volume":"29","author":"Adachi","year":"1999","journal-title":"Jpn. J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2016.11.043_bb0025","first-page":"1681","article-title":"A late phase II study of CPT-11 on uterine cervical cancer and ovarian cancer. Research Groups of CPT-11 in Gynecologic Cancers","volume":"18","author":"Takeuchi","year":"1991","journal-title":"Gan To Kagaku Ryoho"},{"key":"10.1016\/j.ygyno.2016.11.043_bb0030","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1200\/JCO.2003.02.091","article-title":"Phase II trial of irinotecan in patients with metastatic epithelial ovarian cancer or peritoneal cancer","volume":"21","author":"Bodurka","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2016.11.043_bb0035","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1158\/0008-5472.CAN-03-3139","article-title":"Topoisomerase I-mediated inhibition of hypoxia-inducible factor 1: mechanism and therapeutic implications","volume":"64","author":"Rapisarda","year":"2004","journal-title":"Cancer Res."},{"key":"10.1016\/j.ygyno.2016.11.043_bb0040","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s10555-007-9059-x","article-title":"Targeting hypoxia cell signaling for cancer therapy","volume":"26","author":"Melillo","year":"2007","journal-title":"Cancer Metastasis Rev."},{"key":"10.1016\/j.ygyno.2016.11.043_bb0045","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1101\/gad.12.2.149","article-title":"Cellular and developmental control of O2 homeostasis by hypoxia-inducible factor 1 alpha","volume":"12","author":"Iyer","year":"1998","journal-title":"Genes Dev."},{"key":"10.1016\/j.ygyno.2016.11.043_bb0050","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s00432-004-0642-z","article-title":"Anti-angiogenic effects of SN38 (active metabolite of irinotecan): inhibition of hypoxia-inducible factor 1 alpha (HIF-1alpha)\/vascular endothelial growth factor (VEGF) expression of glioma and growth of endothelial cells","volume":"131","author":"Kamiyama","year":"2005","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2016.11.043_bb0055","doi-asserted-by":"crossref","first-page":"5180","DOI":"10.1200\/JCO.2007.12.0782","article-title":"Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer","volume":"25","author":"Cannistra","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2016.11.043_bb0060","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.ygyno.2006.05.006","article-title":"Salvage bevacizumab (rhuMAB VEGF)-based therapy after multiple prior cytotoxic regimens in advanced refractory epithelial ovarian cancer","volume":"102","author":"Monk","year":"2006","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2016.11.043_bb0065","doi-asserted-by":"crossref","first-page":"5165","DOI":"10.1200\/JCO.2007.11.5345","article-title":"Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study","volume":"25","author":"Burger","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2016.11.043_bb0070","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1200\/JCO.2007.12.1939","article-title":"Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia","volume":"26","author":"Garcia","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2016.11.043_bb0075","doi-asserted-by":"crossref","first-page":"3731","DOI":"10.1002\/cncr.25967","article-title":"Combined weekly topotecan and biweekly bevacizumab in women with platinum-resistant ovarian, peritoneal, or fallopian tube cancer: results of a phase 2 study","volume":"117","author":"McGonigle","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.ygyno.2016.11.043_bb0080","first-page":"29","article-title":"Irinotecan in epithelial ovarian cancer","volume":"16","author":"Gershenson","year":"2002","journal-title":"Oncology (Williston Park)"},{"key":"10.1016\/j.ygyno.2016.11.043_bb0085","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1158\/1078-0432.CCR-06-2309","article-title":"Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma","volume":"13","author":"Vredenburgh","year":"2007","journal-title":"Clin. Cancer Res."},{"issue":"Suppl. 2","key":"10.1016\/j.ygyno.2016.11.043_bb0090","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.3747\/co.v18i0.939","article-title":"Progression-free survival in advanced ovarian cancer: a Canadian review and expert panel perspective","volume":"18","author":"Oza","year":"2011","journal-title":"Curr. Oncol."},{"key":"10.1016\/j.ygyno.2016.11.043_bb0095","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(89)90015-9","article-title":"Optimal two-stage designs for phase II clinical trials","volume":"10","author":"Simon","year":"1989","journal-title":"Control. Clin. Trials"},{"key":"10.1016\/j.ygyno.2016.11.043_bb0100","doi-asserted-by":"crossref","first-page":"3731","DOI":"10.1158\/0008-5472.CAN-04-0074","article-title":"Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors","volume":"64","author":"Tong","year":"2004","journal-title":"Cancer Res."},{"key":"10.1016\/j.ygyno.2016.11.043_bb0105","doi-asserted-by":"crossref","first-page":"2729","DOI":"10.1158\/0008-5472.CAN-06-4102","article-title":"Effect of vascular normalization by antiangiogenic therapy on interstitial hypertension, peritumor edema, and lymphatic metastasis: insights from a mathematical model","volume":"67","author":"Jain","year":"2007","journal-title":"Cancer Res."},{"key":"10.1016\/j.ygyno.2016.11.043_bb0110","first-page":"579","article-title":"An early phase II study of CPT-11 in gynecologic cancers. Research Group of CPT-11 in Gynecologic Cancers","volume":"18","author":"Takeuchi","year":"1991","journal-title":"Gan To Kagaku Ryoho"},{"key":"10.1016\/j.ygyno.2016.11.043_bb0115","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1200\/JCO.2013.51.4489","article-title":"Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial","volume":"32","author":"Pujade-Lauraine","year":"2014","journal-title":"J. Clin. Oncol."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825816316122?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825816316122?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T03:13:22Z","timestamp":1749784402000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825816316122"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2]]},"references-count":23,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,2]]}},"alternative-id":["S0090825816316122"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2016.11.043","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2017,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phase II study of irinotecan in combination with bevacizumab in recurrent ovarian cancer","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2016.11.043","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}